| Literature DB >> 23136291 |
Davidson H Hamer, David R Marsh, Stefan Peterson, Franco Pagnoni.
Abstract
Entities:
Mesh:
Year: 2012 PMID: 23136291 PMCID: PMC3748516 DOI: 10.4269/ajtmh.2012.12-0505
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345
Global iCCM implementation research agenda*
| Front-line health workers |
| 1. What is the effect on the performance of CHWs when management of one or more disease is added to their existing responsibilities? |
| |
| |
| 4. Are CHWs able to assess, classify, and treat various illnesses under integrated CCM? |
| 5. What are the best ways to improve and sustain performance of CHWs? |
| 6. What are the costs and performance of different training methods for (illiterate/literate) CHWs? |
| 7. What are the best methods for evaluating the quality of services provided by CHWs? |
| 8. What is the optimal number of CHWs to give near universal coverage to a given geographic area? |
| |
| |
| 11. What are the best ways of supervising CHWs? |
| 12. Which factors increase recruitment and reduce attrition? |
| 13. Which methods of remuneration/incentivization are effective and sustainable? |
| |
| Implementation |
| 15. What is the cost and cost-effectiveness of iCCM? |
| 16. What are appropriate methods for cost recovery and financing? |
| 17. How can effective coverage be achieved by CCM (equity, community effectiveness, etc.)? |
| |
| 19. How can the private sector become involved in delivering |
| 20. How acceptable are CHWs to the health system, and how can CCM requirements for drugs, supplies, supervision, etc. be met? |
| 21. What are health system effects of CCM on referral patterns to and caseload and case mix at first level health facilities? |
| 22. What is the effect of iCCM on antibiotic resistance? |
| 23. What is the impact of iCCM on drug use and therapeutic outcomes in the community? |
| |
| Management of illness |
| 25. How can available tools (RDTs, clinical signs, timers, drugs, pulse oximeters, etc.) be combined into clinical algorithms? |
| 26. What is the algorithm performance in different epidemiologic and health system contexts? |
| |
| 28. What is the appropriate duration of antibiotic treatment of WHO-defined non-severe pneumonia in African settings? |
| 29. Can CHWs treat WHO-defined severe pneumonia in the community? |
| 30. How can age-dose regimens for different drugs be harmonized, and what are the effects on treatment of different packaging techniques? |
| 31. What is the impact of pre-referral drugs on clinical outcomes of children with severe disease? |
| |
| 33. What is the most appropriate antibiotic for treatment of pneumonia? |
| 34. What is the most appropriate formulation of antibiotics? |
| Families and caregivers |
| 35. Do family members recognize the disease and promptly seek care? |
| 36. What are the elements that facilitate family members to use CCM services? |
| 37. Do family members follow treatment recommendations properly? |
| |
| |
| 40. How does prescription of multiple medicines for multiple diseases (e.g., malaria and pneumonia) impact on adherence? |
| |
| Impact |
| 42. What is the impact of iCCM on health and survival of children? |
| 43. Does iCCM lead to increased penetration in terms of reaching the poor? (effective coverage) |
| |
New additions to the list of research priorities are indicated in bold. iCCM = integrated community case management; CHW = community health worker; RDT = rapid diagnostic test; WHO = World Health Organization.